Ganitumab failure in pancreatic cancer another setback for Amgen/Takeda alliance
02:50 EDT 9 Aug 2012 | SCRIP
Amgen and its Japanese development partner Takeda have halted the GAMMA Phase III multinational trial with ganitumab (AMG 479), after an interim analysis showed that the monoclonal antibody was likely to miss its overall survival primary endpoint i..
Original Article: Ganitumab failure in pancreatic cancer another setback for Amgen/Takeda alliance
More From BioPortfolio on "Ganitumab failure in pancreatic cancer another setback for Amgen/Takeda alliance"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
